Press Releases

A recent research effort spearheaded by experts at Roswell Park Comprehensive Cancer Center demonstrates a way to exploit drug side effects in order to prime tumors to support better responses to immunotherapy. Newly published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), the study outlines a novel finding with significant implications for clinical care and research.

A team of researchers from Roswell Park Comprehensive Cancer Center and the Markey Cancer Center in Lexington, Kentucky, report that the efficacy of doxorubicin, a widely used chemotherapy drug, was enhanced in preclinical lymphoma models when it was combined with propranolol, a beta-2 adrenergic receptor (β-AR) blocker commonly used to treat high blood pressure, and which also blocks the effects of stress in the body. The approach illustrates the team’s findings that the metabolic fitness of myeloid-derived suppressor cells (MDSCs) — white blood cells that can suppress the immune system and support tumor growth and metastasis — limits response to therapy.

Obesity is associated with a higher risk of developing at least 13 types of cancer — and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment — an irregularity called “the obesity paradox.” In light of obesity’s detrimental effects in other cancers, what accounts for those unexpected outcomes?

Researchers from Roswell Park Comprehensive Cancer Center will share their latest findings with colleagues from around the world at the 2024 annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, April 5-10. The event attracts more than 21,000 professionals from the oncology field, as well as patients, survivors and advocates.

For individuals living with early-stage prostate cancer, experts at Roswell Park Comprehensive Cancer Center now offer an advanced, safe and painless option to treat the disease. The Buffalo-based cancer center is the only provider in Western New York to offer high-intensity focused ultrasound, also known as HIFU.

Roswell Park Comprehensive Cancer Center is intensifying its efforts to increase lung cancer early detection in the greater Buffalo, New York, area by partnering with Denver-based Eon to leverage the health-tech company’s proprietary artificial intelligence patient management software.

Roswell Park Comprehensive Cancer Center is announcing its latest slate of physician promotions, including naming Julia Faller, DO, as Chief Medical Officer.

Expanding access to a breakthrough treatment option for patients with metastatic melanoma, Roswell Park Comprehensive Cancer Center has been approved to administer the newly FDA-approved tumor-infiltrating lymphocyte (TIL) therapy Amtagvi. This “living drug” cell therapy is manufactured by Iovance Biotherapeutics.

A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers. The findings, recently published in Cell Reports Medicine, lay the groundwork for further research, including a phase 1 clinical trial of colon cancer patients that is currently underway.